Skip to main
BSX

Boston Scientific (BSX) Stock Forecast & Price Target

Boston Scientific (BSX) Analyst Ratings

Based on 22 analyst ratings
Buy
Strong Buy 50%
Buy 45%
Hold 5%
Sell 0%
Strong Sell 0%

Bulls say

Boston Scientific is a company with a strong market presence and a broad range of products in the cardiovascular and med-surg markets, leading to double-digit revenue growth and strong profitability. Despite a recent dip in sales for their WATCHMAN product, the company's diverse product pipeline and cost reduction efforts should support future earnings growth. With a valuation below that of their competitors and potential for upside from new products and M&A, we maintain a Buy rating for this stock.

Bears say

Boston Scientific is facing several headwinds, including a slowdown in WATCHMAN sales, workflow challenges for physicians, recent clinical trials impacting sales, and reductions in physician reimbursement for stand-alone procedures. These factors are expected to lead to flat sequential sales in 2Q and 3Q 2026, and a decline in sales in 2026. However, the company remains confident in its organic revenue growth and profitability targets. Despite these headwinds, our model forecasts a 6% organic growth in 2027 and 2028, warranting a 16.0x P/E multiple. Nevertheless, there are also risks to our rating, including FTC review, competition, acquisition hurdles, and regulatory and clinical trial risks.

Boston Scientific (BSX) has been analyzed by 22 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 45% recommend Buy, 5% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Boston Scientific and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Boston Scientific (BSX) Forecast

Analysts have given Boston Scientific (BSX) a Buy based on their latest research and market trends.

According to 22 analysts, Boston Scientific (BSX) has a Buy consensus rating as of Jul 17, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $78.73, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $78.73, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Boston Scientific (BSX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.